ESR1 Mutations Prevalent in Some Breast Cancers.
A recent analysis of cell-free DNA from blood samples found that ESR1 mutations are highly prevalent and associated with worse overall survival in women with advanced estrogen receptor-positive breast cancer that progressed on aromatase inhibitor therapy. The data also show that patients' mutation status may affect their response to the mTOR inhibitor everolimus.